Join the conversation, follow our blogs and get up-to-the-minute news and health information from UK HealthCare.
A Passion for Cleft Care »
Community Matters »
Markey Menu »
Saddle Up Safely »
UK HealthCare Delivers »
UK HealthCare patients have great stories to tell.
Read Margaret's story »
Read Nicole's story »
Read Mike's story »
See more patient stories »
LEXINGTON, Ky. (June 30, 2015) ̶ Robert “Bo” Cofield has been named vice president/chief clinical operating officer (CCOO) at UK HealthCare effective mid-August. He currently serves as associate vice president for hospital and clinics operations at University of Virginia Medical Center.
In this newly created position at UK HealthCare, Cofield will lead clinical operations for the UK HealthCare enterprise and will be accountable for the operations of UK HealthCare hospitals, managed facilities, ambulatory and provider-based clinics, off-campus and outreach clinics, ancillary services, and the infrastructure to support such operations, including information management and technology. In addition, he will be a member of an executive leadership team that includes Mark Birdwhistell, vice president for administration and external affairs; Murray Clark, senior vice president for health affairs and chief financial officer; and Dr. Frederick de Beer, vice president for clinical academic affairs and dean of the College of Medicine. "As we prepare to operationalize our newly developed strategic plan, we will look to Cofield to lead our key strategic activities in quality and safety, operational efficiency and effectiveness, patient centeredness and the creation of a service line structure," said Dr. Michael Karpf, UK executive vice president for health affairs. "He will also be responsible for building upon our achievements in ambulatory care by leading the effort around our ambulatory strategy as well as the crucial work that must be done to prepare us for value-based health care delivery. With the assistance of key partners from within the physician, clinical operations, nursing leadership and finance areas, he will serve on an interdisciplinary team to help benchmark our clinical measures and cost structure in order to drive reductions in clinical variation and improve operating efficiency." In his current role at UVA, which he has held since February 2010, Cofield has been responsible for the effective management of the UVA Medical Center’s clinical services and operations. He also has directed implementation of the strategic direction of the UVA Health System within the hospital and clinics. He arrived at the UVA Medical Center after serving 10 years in a variety of roles within the University of Alabama at Birmingham (UAB) Health System, including chief operating officer of UAB Highlands Hospital and associate vice president of the 908-bed University of Alabama Hospital. “As I’ve followed your growth at UK HealthCare,” Cofield said, “I recognized a similar focus as my own on the delivery of high-quality, cost-efficient patient care within a culture of patient safety and employee engagement. I believe in both the development and recognition of excellent service, and I see in the people of UK HealthCare a similar commitment to exceptional care and service to meet the very real health care needs of the people of Kentucky.” Cofield completed an administrative fellowship at Tulane University Hospital and Clinics and received the Master of Health Administration and Doctor of Public Health degrees in health systems management from the Tulane University School of Public Health and Tropical Medicine. He is a graduate of Hampden-Sydney College and a Fellow of the American College of Healthcare Executives. He has been active in his local community and has served on the boards of several area nonprofits and community organizations.
LEXINGTON, Ky. June 30, 2015 — Since its first class graduated in 1960, the University of Kentucky College of Nursing has modeled innovation and excellence in nursing education. The program has prepared thousands of men and women nurses who have helped lead our county’s health care system as caregivers, executive leaders, impactful teachers, trail-blazing researchers, policy makers and community transformers.
The UK College of Nursing strives to empower students and faculty to reach their full potential in the nursing profession, whether in health care settings, the board room, classrooms settings or the community. Undergraduate bachelor's of science in nursing (BSN) students receive a high-quality education with opportunities for both academic learning and clinical experience – predominantly at the UK HealthCare. Graduates of the BSN program have a first-time pass rate of 97 to 100 percent for the NCLEX (nursing boards), which exceeds national averages.
The program is renowned for offering nurses advanced-level training, including the nation's first-ever Doctor of Nursing Practice (DNP) for nurses with aspirations to lead as advanced practice nurses or at the executive level. Through its Ph.D. in Nursing program, which has been ranked sixth in the country by the National Research Council since 2010, the college mentors the next generation of great nursing scientists, educators and leaders.
In a spirit of collaboration characteristic of the nursing profession, faculty members in the UK College of Nursing partner with departments within the university and health care organizations across the state to work toward solutions to health challenges in Kentucky.
Ranked 21st for NIH funding among all public and private nursing schools, with a $16 million research portfolio, faculty members and graduate students explore the most pressing health care issues affecting Kentuckians, including pre-term births, cancer, tobacco use and cardiovascular disease.
Dean Janie Heath holds firmly to a vision of raising the college's status to one of the top tier nursing programs in the country.
“The college is transforming nursing education by creating innovative learning and practice environments that are collaborative and team-based to meet the demands of new health care delivery models, and is affecting policy at the highest level possible. This is not only raising the status of the college, but is also improving the health and wellbeing of our patients, our families, our communities, and our country’s health care systems.”
The following timeline chronicles the development of the UK College of Nursing:
1956: Kentucky legislators approve the building of a new medical center on the University of Kentucky Campus.
1957: The creation of a new hospital in a time where physicians were already hard to come by worsened with the realization that nurses, too, were in short hand. In Kentucky, only 13 schools offered hospital diploma programs. Combined, these programs graduated 297 nurses in the 1957 class. Because of this draught, William R. Willard, founding dean of the Albert B. Chandler Medical center and dean of the UK College of Medicine, proposed the idea of a College of Nursing. Willard’s college would offer two programs: one for high school graduates and second for registered nurses.
1958: With the idea of the College of Nursing coming to fruition, Willard found a dean for the College of Nursing in 35-year-old Marcia Allene Dake, a doctorate of education student at Columbia University’s Teacher’s College, would become the nation’s youngest dean of a nursing school.
1959: With the appointment of Dake in 1958 came the need to hire more faculty members. Three more women, all with master's degrees in nursing, were appointed within the next year.
1960: In May of 1960, the College of Nursing enrolled the 35 women that would make up the first class. Of these women, five were registered nurses while the remaining 30 were just beginning their education. These women faced many of the same rules University of Kentucky students in the College of Nursing are subjected to today: white shoes, no nail polish and no flashy jewelry.
1962: During the next two years, enrollment into College of Nursing nearly doubled from 40 in 1960 to 74 in 1962. In order to address the growth of the program, Dake teamed up with Henderson Community College to establish an associate's degree program. Once the program at Henderson was established successfully, programs opened at community colleges in Lexington and spread to Covington and Elizabethtown. In 1967, four years after the first partnership, more than 30 percent of new nurses in Kentucky had graduated from one of the associate degree programs.
1964: The College of Nursing graduated its first class. As an established part of the University of Kentucky Medical Center, the college was now offering not only an undergraduate program, but also a continuing education program and the successful associate degree programs.
1965: The College of Nursing was granted full accreditation from the National League for Nursing (NLN). With the expanding reach of the College of Nursing and the success of additional associates degree programs, Dake began the process of creating a graduate program within the College of Nursing. Her hope was that the graduate program would eventually produce nurses with the qualifications to become professors.
1969: The first class of graduate students begins their coursework in September. There were nine students.
1971: Dake resigns her position of Dean of the College of Nursing. During her tenure as Dean, Dake and her colleagues helped to establish a new curriculum that would spread nationwide during the 1960s and 1970s.By the time Dr. Dake resigned, the enrollment in the College of Nursing had grown nearly 350 percent, from 35 women in 1964 to 512 undergraduate students in 1971.
1972: Marion McKenna is appointed Dean of the College of Nursing. Aware of the exponential growth the College of Nursing was facing, McKenna was hired on the condition that a new facility be created to house her school.
1975: The College of Nursing established nursing programs at Hazard Community College and Kentucky Wesleyan College in Owensboro in hopes to make nursing education accessible to nontraditional and rural students.
1979: McKenna proposes the discontinuation of the baccalaureate program in order to focus solely on trained registered nurses. However, the plan was not successful and the original basic baccalaureate program was reinstated in May 1981.
1980: The Delta Psi chapter of Sigma Theta Tau is established at University of Kentucky. Later in the year, McKenna begins the process of establishing a doctoral program in the College of Nursing.
1984: The College of Nursing announces Carolyn Williams as the new dean. Williams knew the importance of research and publications and emphasized the idea that it would be required as the college continued to advance.
1985: In June 1985 Williams’ doctorate program was approved and in 1987 the first doctoral student enrolled in the program.
1992: The first class of doctorate students graduate with a Ph.D.
2001: The College of Nursing begins to offer a Doctor of Nursing Practice (DNP) Program, the first in the nation. The DNP program prepares nurses for advanced practice, clinical leadership and executive positions in health care systems. The first class of DNP students graduated in 2005.
2006: Williams resigns as dean and rejoins the faculty. Jane Kirschling becomes the fourth dean of the College of Nursing.
2006: The Ph.D. program begins its Post-BSN Option, which builds on the BSN degree and prepares nurses researchers at the doctoral level.
2007: The first class is inducted into the College of Nursing Hall of Fame. The College of Nursing successfully doubled undergraduate student enrollment in the BSN program – from 80 students to 160 students – in an effort to alleviate nursing shortages in Kentucky and across the nation.
2008: Kirschling and Jay Perman, dean of the College of Medicine, established a work group to evaluate interest in Interprofessional Education (IPE) curriculum for the Medical Center – the IPE curriculum was approved in 2010.
2009: The Masters of Science in Nursing program is ended, and becomes part of the DNP program. Post Baccalaureate students are now able to directly enroll in the DNP program.
2010: College celebrates its 50th anniversary and inducts the second class of the College of Nursing Hall of Fame.
2011: The second class is inducted into the College of Nursing Hall of Fame.
2012: Patricia Howard is appointed interim dean.
2013: College of Nursing partners with Norton HealthCare to offer DNP program to practicing nurses.
2014: Janie Heath is appointed as the fifth dean of the College of Nursing.
MEDIA CONTACT: Elizabeth Adams, email@example.com
LEXINGTON, Ky. (June 29, 2015) — The quickest way to ruin a fun-filled summer day is to come in contact with a nasty patch of poison ivy or poison oak. Touching any parts of these plants can result in a red and itchy skin rash characterized with tense blisters and bright red lesions. Here’s all you need to know about how to spot and treat the pesky weeds.
Q: What do poison ivy and poison oak look like?
A: Each leaf of both poison ivy and poison oak has three small leaflets and both can grow as shrubs or vines. In the spring, poison ivy grows yellow-green flowers and poison oak may have yellow-white berries.
Q: What causes the rash?
A: The rash is caused by contact with urushiol, a sticky oil found in all parts (leaves, roots, stems), of both alive and dead poison ivy and poison oak. Approximately 85 percent of people will break out in an allergic reaction after touching the plant. The allergic reaction is delayed and usually starts 1-3 days after exposure.
Q: Are poison ivy and poison oak rashes contagious?
A: No, the rash is only spread through the oil. You can't catch a rash from someone else by touching their rash; however, you can get the rash by touching anything that has come in contact with the plant's oil, such as clothes, sporting gear, or especially pet fur.
Q: What are the symptoms?
A: The most common symptoms of the rash are itchiness, red linear streaks or blisters where the plant brushed against the skin, characterized by small to large sized bright red lesions, and blisters that may leak a clear to yellow fluid.
Typically, the rash from poison ivy or poison oak will last about 10 days to three weeks. But in more severe cases, it could take up to six weeks to go away. It clears much more quickly with medical intervention.
Q: How can the rashes be treated?
A: Immediately after you think you have come in contact with the plant, wash your skin with a mild soap and cool water. It can help reduce the amount of oil that causes the allergic reactions.
For an effective home treatment, compress the affected areas with a clean cloth soaked in whole milk for 10 to 15 minutes three to four times daily to dry up the blisters, followed by an over-the-counter topical one percent hydrocortisone cream.
Calamine lotion can be an effective astringent. Application of the aloe plant can also help with the itching. Antihistamines like Benadryl are not affective in helping with the rash.
Additionally, make sure you wash your clothes or any other objects that may have come in contact with the plant to prevent the plant’s allergic chemical from spreading even more.
Medical treatment from a physician would include a prescription topical steroid and systemic steroids to hasten the clearing.
Dr. Stuart Tobin is Division Chief of Dermatology for UK HealthCare.
This column appeared in the June 28, 2015 edition of the Lexington Herald-Leader
LEXINGTON, Ky. (June 26, 2015) — Researchers at the University of Kentucky's Sanders-Brown Center on Aging have completed a study that revealed differences in the way brain inflammation -- considered a key component of AD — is expressed in different subsets of patients, in particular people with Down syndrome (DS) and AD.
People with Down syndrome have a third copy of Chromosome 21, and that chromosome is the same one responsible for the production of a molecule called amyloid precursor protein. Amyloid overproduction can lead to brain plaques that are a cardinal feature of Alzheimer’s, so it is not surprising that nearly 100 percent of people with Down syndrome develop Alzheimer’s disease pathology in their brain by the time they are 40.
“People develop Alzheimer's disease at different ages, but it's typically in their 60s, 70s, or 80s,” said Donna Wilcock, Ph.D, an assistant professor at the Sanders-Brown Center on Aging and principal investigator for the study. “It’s a little easier to study Alzheimer’s disease in Down syndrome because of the predictability of the age when adults with DS develop signs of the disease.”
In Wilcock's study, some interesting data emerged that will shape the way scientists look at AD as manifested in various subsets of the population. Using brain autopsy tissue from a group of people — some with DS/AD, some with AD alone, and some healthy, Wilcock and her team were able to determine differences in the way neuroinflammation was expressed in people with DS.
In previous studies where Wilcock and her colleagues identified different types of inflammation in AD brains,, two families of inflammatory markers — called M1 and M2a — were each present to varying degrees in the sample population representing early AD cases, indicating a notable level of heterogeneity in the way the AD disease process begins in the brain. But in the late-stage AD cases, there was a high degree of homogeneity with high levels of the markers M1, M2 and M2c.
"If you think of it in terms of a roadmap, there is almost always more than one way to get from Point A to Point B, and that seems to be the case in disease progression as well," said Wilcock.
In this most recent study, the team found that the inflammatory response in DS/AD brain tissue was significantly greater than that in tissue from AD patients. Further, there was an elevated level of markers for M2b,that was not replicated in tissue from sporadic (i.e. ideopathic) AD cases. In other words, AD in the DS brain had a very different neuroinflammatory profile than AD in people without DS.
"It has been generally assumed that AD presents the same way in people with Down syndrome as it does in people without DS, but our work demonstrates that this is not the case," said Wilcock. "This will have important implications for the study of AD treatments, as some treatments might be effective with people without DS but not those with DS, and vice-versa."
Wilcock’s work has been published online in the Neurobiology of Aging. This study was part of a larger DS Aging study at the Sanders-Brown Center on Aging funded by NIH/NICHD (Head and Schmitt), and was also funded by a research grant awarded to Dr. Wilcock through a partnership between the Alzheimer’s Association, the Global Down Syndrome Foundaiton and the Linda CRNIC Institute for Down syndrome.
The Sanders-Brown Center on Aging is one of the world's leading research centers on age-related diseases. SBCoA improves the health of the elderly through research, education and outreach programs related to understanding the brain's aging process and managing age-related cognitive impairment.
"When someone has a heart attack, we shift into maintenance mode by prescribing medicines and other treatments to prevent another heart attack, but we can't reverse the damage that's already done," said Dr. Ahmed Abdel-Latif, assistant professor at the University of Kentucky's Gill Heart Institute. "With all of our advances in cardiovascular medicine, there is currently only one approved way to repair damaged heart tissue after a heart attack: with a heart transplant."
An average of 21 people die every day in the U.S. waiting for an organ transplant, according to the Organ Procurement and Transplantation Network (OPTN) and the Gift of Life Donor Program. Clearly, transplant isn't a very elegant solution due to the limited number of donor hearts available and the lifetime of maintenance required to avoid complications post-transplantation, Latif said. Furthermore, heart transplants often aren't a viable option for the very sick or those with co-morbidities such as pulmonary hypertension. But stem cells —which have the potential to grow into a variety of heart cell types — might repair and regenerate damaged heart tissue, and research at the Gill Heart Institute is looking into that concept.
"There are very few U.S. centers offering regenerative medicine for cardiovascular disease," Latif said. "We are an active lab with a full spectrum of studies exploring translational opportunities for stem cell therapy."
One such study, called ALLSTAR (ALLogenic cardiac Stem cells to Achieve myocardial Regeneration) is looking into the possibility that stem cell therapy can repair damaged heart tissue after a recent heart attack. These patients often suffer long-term consequences of their heart attack, slipping into heart failure and potentially requiring an expensive and risky heart transplant.
Eric Mason is one of the first patients to enroll in the ALLSTAR trial at the Gill. He was just 35 years old when he had a life-threatening heart attack.
"In order for the heart to function properly, it needs to be supplied with sufficient amounts of oxygen-rich blood," Latif said. "The left coronary artery is tasked with this responsibility as it supplies blood to large areas of the heart. When this artery becomes blocked, it will cause a massive attack that will likely lead to sudden death."
Mason had blockages in all three of his arteries — 80 percent, 90 percent and, in the left coronary artery, 100 percent. His type of heart attack is nicknamed "the widow maker" because so few patients survive.
Luckily, Eric's wife, Misty, was alert and acted quickly.
"Eric's father died of a heart attack at age 41, and Eric's symptoms were the same as a friend of ours who also had a heart attack," Misty Mason said. "So when he called to tell me it felt like an elephant was sitting on his chest, I told him to take two baby aspirin and get to the emergency room."
Eric Mason was taken to the cath lab at the Gill Heart Institute from the emergency room in Richmond. There, Latif inserted three stents — small devices that prop open blocked arteries, restoring blood flow. But while the stents helped prevent further injury, his heart attack had already caused a dangerous amount of irreversible damage.
Before Eric left the hospital, Latif approached him about joining the ALLSTAR study.
"Eric was an ideal candidate for the study because younger patients with moderate to severe damage to the heart muscle are the ones most likely to benefit from stem cell therapy," Latif said. "Without treatment, it's likely Eric would spend a lifetime crippled by heart failure and/or require a heart transplant."
Eric was anxious at first about participating in the study but with the encouragement of his uncle, a primary care physician and UK graduate, he quickly realized it was a unique opportunity to help himself and others in the same situation.
"My uncle pointed out that it couldn't hurt, and might help," Eric said. "If it helps others to prevent what happened to me, why wouldn't I take the chance?"
Six months after Eric's heart attack, Latif snaked a catheter into Eric's heart from a small incision in Eric's wrist. Positioning the catheter as closely as possible to the area of damaged tissue, Latif released a fluid containing either about 25 million stem cells harvested from the heart tissue of volunteer donors or a placebo.
"An important element of all research is the comparison in results between people who received the treatment and people who did not, so we don't know yet whether Eric actually received stem cells," Latif said.
Now comes a period of watchful waiting and regular testing, including echocardiograms, to assess whether Eric's ejection fraction — a measure of the heart's ability to pump blood - improves long-term, and, if so, whether that improvement is a result of the stem cell therapy.
The active part of the study is one year, but Latif will follow Eric's progress for five years to assess the treatment's effectiveness over time.
"This treatment has enormous potential to improve the lives of thousands of people who suffer heart attacks each year," Latif said. "When someone donates their heart today, it can saves the life of one other person, but if we are able to harvest stem cells from one donor heart, we might be able to save the lives of dozens of people."
"If the study demonstrates this treatment's effectiveness, it will revolutionize cardiac care."
In the meantime, this former two-time state amateur golf champ and father of two daughters, ages 5 and 2, has returned to his job as manager for a golf club in Booneville, quit smoking, improved his diet and exercise regimens, and counted his blessings.
"I played in my first golf tournament when I was 12 years old, and that's the same year my dad died of his heart attack," Eric said. "I plan to be around to walk Erica and Rylee down the aisle, and being a part of this research is one way I can make sure that happens."
Media Contact: Laura Dawahare, firstname.lastname@example.org
LEXINGTON, Ky. (June 25, 2015) – The inaugural Thomas V. Getchell, Ph.D., Memorial Award has been presented to Erica Littlejohn, a doctoral candidate and graduate student at University of Kentucky.
Getchell was a professor in the Department of Physiology and a member of the UK Sanders-Brown Center on Aging and served as Associate Dean for Research and Basic Science for the College of Medicine from 1989 to 1998.
The award was created to honor Getchell, who died July 20, 2013, and to support an annual travel stipend for a student participating in the Grant Writing Workshop. Getchell founded the Grant Writing Workshop in 2005 with a vision to provide proactive, individualized mentoring to graduate students, MD/PhD students and postdoctoral trainees to further their training in grantsmanship, increase their success rate in obtaining fellowship grants and enhance their research careers.
“The award was established to honor Tom's enduring commitment to and talent for mentoring post-doctoral and graduate students in the skills needed to become successful scientists, and to honor his achievements as a scientific researcher and teacher during a long and productive career," Dr. Marilyn Getchell, wife of Getchell, said.
Littlejohn participated in Getchell’s Grant Writing Workshop in 2012. Her areas of study as a graduate student focus on traumatic brain injury and neurogenesis. In addition to publishing scientific articles in peer-reviewed journals, Littlejohn has been the recipient of numerous travel awards to present her research at national conferences.
“It’s not enough to strive for excellence in science and research, I believe a person’s legacy is measured in the lives they touch, and Tom Getchell exemplifies this narrative,” Littlejohn said. “I hope to support others with my commitment to increasing diversity in health sciences and through mentorship.”
Littlejohn received her bachelors of science degree in microbiology from the University of Iowa. She is currently president of the University of Kentucky Black Graduate and Professional Student Association (BGPSA) and serves as a student mentor in the UK-EKU Bridge to Doctorate Program, which aims to increase participation of underrepresented students in science disciplines.
She has served as an undergraduate mentor at GEM Consortium events to help recruit students from underrepresented populations to pursue graduate degrees in science, technology, engineering and mathematics.
Getchell continually challenged students to do excellent and meaningful work. He infused his workshops with humor through the retelling of his own personal anecdotes and treated students with the utmost respect, exemplified by his signature weekly communiqués which all began “Dear Colleagues…”.
To date, workshop trainees have earned more than $2.4 million in fellowship funding as a result of Getchell’s efforts.
MEDIA CONTACT: Allison Perry, (859) 323-2399 or email@example.com
LEXINGTON, Ky. (June 25, 2015) – Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women.
The HPV vaccination series consists of three shots and helps prevent HPV infection and cervical cancer. Previous studies have shown that cost, lack of transportation, cultural views, and lack of knowledge about cervical cancer prevention as well as limited support from health care providers has prevented Appalachian women from getting or completing HPV vaccination in the past.
The concept of fatalism as it relates to health asserts that individuals perceive themselves to have limited control over what happens to their health and that health outcomes may be determined by fate. Previous research has found that some Appalachian women have reported fatalistic beliefs regarding their health, including the perception that being diagnosed with or preventing cancer is out of their control.
Published in The Journal of Rural Health, the study involved research nurses administering the first dose of the HPV vaccine series free of charge to Appalachian Kentucky women aged 18-26. The young women were then surveyed about their beliefs regarding cancer and followed for nine months after receiving the first dose to determine vaccination series completion; nearly 350 women participated in the study.
The study found that women who held fatalistic beliefs about their perceived lack of control over their health and cervical cancer had a significantly lower likelihood of completing the HPV vaccination series.
According to the Centers for Disease Control and Prevention, HPV is the most common sexually transmitted infection in the United States, affecting more than 79 million people. Nationally, Kentucky has some of the highest rates of HPV-related cancers; according to the Kentucky Cancer Registry, these elevated cancer rates are primarily attributable to cancer disparities observed in the 54-county Appalachian region of the state.
Almost all cervical cancers are caused by HPV, and several other cancers are linked to the virus as well, including head and neck, anal, penile, vulvar, and vaginal malignancies. Completing the vaccination series is the best way for young women (and men) to protect themselves against HPV infection and HPV-related cancers.
Personal beliefs like fatalism can serve as barrier to preventive health care measures such as HPV vaccination. Findings from the study indicate that fatalistic beliefs should be addressed in a culturally sensitive manner through education and tailored communication messaging. Such efforts may help increase HPV vaccination rates and decrease cervical cancer rates in Appalachian Kentucky.
"Results from this study may encourage health care providers to proactively assess and address young women’s personal health beliefs and develop a strategy for helping them complete the HPV vaccination series," Robin Vanderpool, associate professor in UK's Department of Health Behavior and deputy director of the Rural Cancer Prevention Center, said.
LEXINGTON, Ky. (June 25, 2015) — University of Kentucky College of Dentistry graduate Jonathan Francis and Assistant Professor Lina Sharab were recognized for their research efforts by the American Association of Orthodontists (AAO), and they presented their research during the recent 2015 AAO Annual Session in San Francisco. The AAO is the world’s oldest and largest dental specialty organization, representing more than 17,000 orthodontist members throughout the United States, Canada, and abroad.
Francis was awarded second place, receiving $750, in the basic science category of the 2015 Charley Schultz Resident Scholar Award for his research titled, “Screw Diameter and Orthodontic Loading Influence Adjacent Bone Response.” A total of 23 research presentations were submitted for the award this year. Francis also received second place for this research in the UKCD College Research Day in the Graduate Student Clinical/Translational category. His mentor was UKCD Division of Orthodontics Chief Dr. Sarandeep Huja.
The Charley Schultz Resident Scholar Award was established by the AAO in 2004 as a means of offering graduate students/residents the chance to present clinical science and basic science research using narrative material and a posterboard.
"It’s exciting to be a part of research that can help advance the field of orthodontics. I am very grateful for all the guidance and help I received throughout this project," Francis said.
Sharab was one of four people awarded the 2015 Thomas M. Graber Award of Special Merit, established by the AAO in 2002, for her research titled, “Genetic and treatment related risk factors associated with external apical root reabsorption (EARR).” Sharab was mentored by UKCD Professor of Orthodontics Dr. James Hartsfield and also supported by Assistant Professor Dr. Lorri Morford, UK Center for Oral Health.
“Most people work hard to have their goals achieved. A variety of life obstacles start filtering away many of the hard working people, slowing them down, or leaving them deeply stressed," Sharab said. "Having enthusiasm as a motivation is the only guarantee to eventually reach one’s goal. When one reaches her/his goal, the best reward is a symbolic gift of the same nature; an award that was passionately created, named after one of the most passionate educators in orthodontics, and given to re-energize and nurture a young growing passion like mine.
"The Graber Award is the most rewarding gift to my love of both orthodontics and education. While it is true that research was required as part of earning the orthodontic degree; it was also a labor of love. I was lucky to get the inspiration and support from my mentors at UK.”
The AAO Awards selection process is very competitive, Huja said. "It is significant that two individuals in the Division of Orthodontics at the University of Kentucky were recognized and received awards in the same year. This is really a tribute to the graduate students’ hard work and the college’s mentors who work diligently to develop these research ideas."
“I am delighted to see these superb young orthodontists receive national attention for the quality of their work. This is yet another indication of the high quality of our orthodontic program,” said Dean Sharon Turner. “Our faculty are world-class as demonstrated by their achievements and, even more impressive, by the achievements of those whom they so carefully mentor.”
LEXINGTON, Ky. (June 22, 2015) — There is growing excitement among headache specialists about initial research into a new class of anti-migraine drugs.
Called CGRP monoclonal antibodies, these drugs appear to significantly reduce the frequency of migraine in human clinical trials.
"We know that levels of CGRP are elevated during migraine attacks and decrease with resolution of the attacks," said Sid Kapoor, MD, Fellow of the American Headache Society and Director of the Headache Program at the University of Kentucky's Kentucky Neuroscience Institute (KNI). "This new class of drugs aims to reduce CGRP levels either by inactivating CGRP or disabling the receptor that binds to it, effectively disrupting the chain of events that causes migraine pain."
These drugs have significant potential to change the landscape for migraine treatment, Kapoor said.
"Currently, my only course of action is to patiently and methodically work through a morass of drugs for blood pressure, depression, or epilepsy, and if those don't work, it's on to more complex and expensive therapy options like Botox," Kapoor said. "It's a frustrating process for both the doctor and the patient."
"If these CGRP drugs can deliver as promised, they will represent the first new class of anti-migraine drugs in more than 20 years -- and those only treated migraines after they occurred, and rarely prevented them."
What's particularly exciting to headache specialists is the profound effect the drugs appear to have on migraine incidence. Initial results from Phase II studies on each of the four drugs currently in development reveal huge reductions in the incidence of migraine — one drug, from Alder BioPharmaceuticals, has demonstrated reductions from 50 percent to almost 100 percent.
So why aren't these drugs being rushed to market? Not so fast, Kapoor said.
"We don't yet fully know how blocking CGRP affects other organ functions long term. Previous attempts at modifying this pathway were too dangerous for patients and studies had to be discontinued. It is exciting that we are succeeding with a fresh approach."
CGRP monoclonal antibody drugs are at least five years away from public distribution. The next step is Phase III trials, which aim to establish efficacy and long-term safety compared to a placebo.
"Pain studies are notorious for a high placebo response and hence this step will be critical," Kapoor said.
According to the American Headache Society, more than 36 million Americans suffer from migraine attacks, and about four million of those people experience more than 15 migraine days a month. Migraine can be extremely disabling and costly, accounting for more than $20 billion in direct and indirect expenses each year in the United States.
The Best Places Organization ranks U.S. cities by migraine prevalence according to several factors, including the number of migraine-related drug prescriptions per capita, lifestyle and environmental factors, and the consumption of migraine-triggering foods. The Cincinnati Metropolitan Area, which includes large parts of Northern Kentucky, ranks first, and both Louisville and Lexington are in the top 30.
"Our hope is that KNI will be a Phase III test site," Kapoor said. "We have notable expertise in migraine treatment, and we are located at the epicenter of migraine incidence."
LEXINGTON, Ky. (June 22, 2015) — In a corner of Larry Goldstein's office on the fourth floor of the Kentucky Clinic sits a Captain's chair — a common sight in faculty offices everywhere. But a closer inspection of the emblem on the chair reveals the "Eruditio et Religio" motto of Duke University.
You don't see that often at the University of Kentucky.
"As the (NCAA men's basketball) tournament progressed, I was more and more fatalistic," said Goldstein, who accepted the chairmanship of the UK Department of Neurology in January. "I knew that if UK and Duke played in the final, either way, I couldn't win. The University of Western Siberia was starting to look like a better career option."
But as soon as the conversation veers away from the storied Duke-UK rivalry, he gets serious.
A highly acclaimed expert in stroke and other related neurological disorders, Goldstein comes to UK with a resolve to apply his skills and experience to propel the department — and its sister, the Kentucky Neuroscience Institute — to the next level of research, patient care, education and service.
"There is so much talent here (at UK ) already, and so much to offer Kentuckians in terms of specialty neurology care," Goldstein said. "I hope to organize our resources in a way that maximizes the efficiency of clinical care, clinical research, and translational/biomedical collaborations at the same time we provide service and leadership for the citizens of the commonwealth."
Goldstein received his undergraduate degree from Brandeis University in 1977 and his MD from Mount Sinai School of Medicine in 1981. He then completed his internship and neurology residency at Mount Sinai before venturing to Duke University in 1985 for a research fellowship, where rose through the ranks to become a professor of neurology, chief of the Division of Stroke and Vascular Neurology, director of the Duke Stroke Center and an attending neurologist at the Durham VA Medical Center until his arrival here last month.
Most people are drawn to Kentucky for its unique landscape. Goldstein came to Lexington in part because of something less appealing.
"Kentuckians suffer from strokes at a higher rate than almost anywhere else in the U.S.," Goldstein said. "Since medical school, I've had a focused interest in stroke prevention, acute intervention, post stroke recovery, and systems of care."
"This seemed to be the perfect place at the right time to apply my research focus and career interests." “When I combined this with the opportunity to work with outstanding colleagues at UK to develop programs that will make a real difference in people’s lives, I was convinced there was no better place in the country for me to work.”
Goldstein has published more than 650 peer-reviewed journal articles, editorials, book chapters, abstracts, and other professional papers. He indicated that, “the faculty at Academic Medical Centers are in a unique position to influence public policy for the benefit of the patients we serve.” As a member of the American Heart Association National Spokesperson panel and past national chairman of the AHA Advocacy Committee he is a noted voice in educating the public, medical professionals and policymakers about stroke and cardiovascular disease. By helping to promote the AHA’s adoption of stroke as one of its primary missions, Goldstein assisted with the AHA's initiation of the development of stroke centers and the Get with the Guidelines-Stroke program. He has also supported the specialty of neurology nationally through work on several committees of the American Academy of Neurology.
Goldstein has won numerous awards, including the AHA’s Chairman’s Award, its National Volunteer Advocate of the year, the Stroke Council Leadership Award and the Feinberg Award for excellence in stroke. He has been awarded more than 15 million dollars in grant support throughout his career studying cerebrovascular disease, pharmacological approaches to recovery after stroke, motor recovery, and mechanisms of behavioral recovery after focal brain injury.
His clinical and research interests are complemented by his commitment to educating the next generation of neurologists, and he is particularly proud of his several teaching awards. To that end, Goldstein hopes to enhance programs at UK that foster faculty career development and enhance the Department’s educational programs.
“Dr. Goldstein brings to the university a great balance of clinical experience and research expertise,” said Dr. Frederick C. de Beer, dean of the UK College of Medicine. "His interest and skill in the area of stroke is particularly relevant to our patient population, since cardiovascular events, including stroke, occur at such high rates."
“I am thrilled to be at UK and to have been given the opportunity to work with outstanding colleagues to continue to help build what I am convinced will be one of the best neuroscience programs in the country,” Goldstein said.
LEXINGTON, Ky. (June 19, 2015) — The University of Kentucky's Health Care Committee of the UK Board of Trustees were presented a strategic plan that will guide UK HealthCare through 2020. The committee met Thursday during their annual retreat.
Building upon the success of the past 10 years, the plan continues to emphasize caring for the most complex, critically ill patients in Kentucky and beyond.
Some of the statistics and figures presented that reflect UK HealthCare's growth include:
In approving the new strategic plan, UK HealthCare officials asked for a commitment from its leaders, stakeholders and partners to move forward and achieve its vision by giving latitude for collaborative models, committing to clinical excellence and providing an outstanding patient experience as well as service line integration. From its statewide partners, it was asked for participation in a statewide collaborative that fosters success against the challenges of the future.
"The 2020 Strategy is built on a foundation of patient-centered care and a patient-centered culture that includes growth in complex care as well as ambulatory care; strengthening partnership networks to reduce costs, and increase efficiency; and value-based care and payments which improve predictability of outcomes and cost while adopting evidence-based leading practices," said UK Vice President for Health Affairs Dr. Michael Karpf.
The plan includes developing a cultural change program in order to support the 2020 strategic vision. The program will identify key cultural strengths and opportunities. The goal will be to design a patient-centric experience that positions UK HealthCare to be Kentucky's destination provider for complex care and it will enable staff and leadership to be ambassadors of the patient-centered culture and UK HealthCare brand.
Also detailed in the Strategic Plan is growth in complex care and in ambulatory (outpatient care). As part of this goal, substantial service line growth is needed in the next five years. Additionally, ambulatory specialty care will also need to grow by improving access to UK HealthCare specialists and developing a patient-centered care model as well as partnering with community physicians.
As part of the service line growth, the focus will continue to be on treating the most complex patients and partnering with community providers to keep lower acuity patients in their home community.
Service line areas of primary focus for growth will be the Gill Heart Institute, Kentucky Children's Hospital, Markey Cancer Center, Kentucky Neuroscience Institute, High-Risk Obstetrics and Neonatal Intensive Care, Solid Organ Transplantation, Digestive Health, Musculoskeletal, and Trauma and Acute Care Surgery.
Clinical and support services that UK HealthCare will invest in to enable growth in these service lines includes excellence in quality and operational efficiency; redesigning the transfer management processes in order to create capacity and treat patients in the appropriate care setting and return them to our community partners; and develop a service line operating model to support and coordinate comprehensive, multidisciplinary care across the continuum and community.
These same strategies will be used to expand ambulatory specialty care.
To achieve this plan, a new service line operating model will be implemented to enable and enhance the organization's strategic initiatives. This new model will incorporate the transition from department and specialty driven care to multidisciplinary, multi-specialty care; episodic and high-acuity focused care to disease and cross continuum focused care; from provider centric to patient centric; from individual physician or specialty care to team care delivery involving multiple specialties; and UK HealthCare management of high-acuity care to collaboration with external partners to optimize site and level of care.
Integrated technology that standardizes data across the organization and enables population health management will be utilized.
Another overarching premise of the 2020 Strategic plan is the strengthening of partnership networks including acute care partnerships, post-acute care partnerships, primary care and community care. As part of future planning, UK will develop a primary care network to ensure a seamless experience across the care continuum and position the organization for value-based care and population health.
The third selected strategy in the plan is value-based care. In order to provide enhanced value for patients, UK HealthCare will develop a "best in class" quality management program.
This strategy includes improving the predictability of outcomes, cost of care, and adoption of evidence-based practices throughout the enterprise across all settings of care.
"To be successful, patient care in the future must be affordable, accessible, coordinated, efficient and high quality with a shift to improving health outcomes and rationalizing but not rationing care," said Karpf.
He added that although a significant amount of time and effort has been invested in developing this strategic plan, UK HealthCare’s strategic journey does not end here.
"We will continue with work in the weeks and months to come to set priorities, develop timelines, and track progress and results."
Media Contact: Kristi Lopez, 859-323-6363, Kristi.firstname.lastname@example.org
LEXINGTON, Ky. (June 16, 2015) — Kentucky Gov. Steve Beshear joined child safety advocates at Kentucky Children's Hospital on June 15 to sign a bill aimed at improving safety for child passengers in motor vehicles.
House Bill 315 brings Kentucky’s current booster seat law in line with 31 other states, including all seven neighboring states. The previous law required children younger than 7 years old who are between 40 and 50 inches in height to ride in booster seats before graduating to adult seat belts. The enhanced bill increases the height requirement to 57 inches and the age requirement to 8 years old, the size and age at which children begin to fit properly in adult seat belts.
“Passage of this bill provides greater safety and protection to our most precious asset – our children. I commend the Kentucky Senate and House for their effort on enhancing our existing booster seat law,” Gov. Beshear said.
House Bill 315, which passed with a vote in March, was championed by child safety experts in the Kentucky Injury and Prevention Research Center (KIPRC), the Kentucky State Safe Kids led by KIPRC and the Kentucky Department for Public Health, and the Fayette County Safe Kids Coalition led by Kentucky Children's Hospital. The bill also received support from the Kentucky Office of Highway Safety, safety advocates from Kosair Children’s Hospital, and Safe Kids coalitions, law enforcement officials, emergency responders, pediatricians and booster seat advocates from around the state.
“Motor vehicle crashes are the leading cause of death for children above the age of 1 in Kentucky," Dr. Susan Pollack, a Kentucky Children's Hospital pediatrician, Safe Kids Kentucky coordinator and director of the Pediatric and Adolescent Injury Program at KIPRC, said. "We know many Kentucky children are saved every year, even in serious crashes, by being properly restrained and protected in a booster seat. The revised law gives parents better guidance for safely transporting their children.”
A properly installed, belt-positioning booster seat lowers the risk of injury to children by nearly 60 percent, compared with seat belts alone, according to the National Highway Traffic Safety Administration.
“The reason is simple: Motor vehicle seat belts were designed for adults, not children. The added height of the booster seat enables the child to fit into a seat belt properly,” Transportation Secretary Mike Hancock said.
Effective on June 24, the bill requires law enforcement officers to issue citations with a $30 fine with no court costs. In addition, violators will have the option to purchase a booster seat instead of paying the fine.
Click here for a link to House Bill 315.
For more information about the bill:
Kentucky Office of Highway Safety
National Highway Traffic Safety Administration
Kentucky Children's Hospital
Kentucky Injury Prevention and Research Center
Safe Kids Kentucky
Safe Kids Fayette County
LEXINGTON, Ky. (June 16, 2015) – Retired University of Kentucky professor Dr. Ardis D. Hoven was elected the first female chair of the World Medical Association (WMA) at the organization’s 200th council meeting in Oslo, Norway.
Hoven has served as chair of the American Medical Association delegation to the WMA for the past few years and now will serve a two-year term as chair of the WMA. The WMA is the international organization representing physicians from 111 national medical associations.
“I feel fortunate to have the opportunity to do this,” Hoven said. “I see myself not so much as a woman in this role, but as a leader of a global organization of physicians who are working to support their peers around the world and improve the lives of their patients.”
Born in Cincinnati, Hoven received her undergraduate degree in microbiology and then her medical degree from the University of Kentucky. She completed her internal medicine and infectious disease training at the University of North Carolina at Chapel Hill. Board-certified in internal medicine and infection disease, Hoven is a member of the American College of Physicians, and the Infectious Disease Society of America.
Hoven has been the recipient of many awards, including the University of Kentucky College of Medicine Distinguished Alumnus Award and the Kentucky Medical Association Distinguished Service Award. In 2015, she was inducted into the Hall of Distinguished Alumni for UK. She was president of the Kentucky Medical Association from 1993 to 1994 and served as a delegate to the AMA from Kentucky.
Hoven hopes for the WMA to raise its profile internationally and increase the impact of its policies and advocacy on behalf of physicians and patients.
“I want to make our footprint bigger and our voice stronger,” Hoven said.
Hoven was recently inducted into the UK Alumni Association's Hall of Distinguished Alumni. Click on the video below to watch the role UK played in Hoven's medical career.
Video Produced by UK Public Relations & Marketing. To view captions for this video, push play and click on the CC icon in the bottom right hand corner of the screen. If using a mobile device, click on the "thought bubble" in the same area.
MEDIA CONTACT: Allison Perry, (859) 323-2399 or email@example.com
LEXINGTON, Ky. (June 17, 2015) — The Alzheimer’s Association estimates that every 67 seconds someone in the United States develops Alzheimer’s Disease (AD).
While the news brings an incredible amount of uncertainty to patients and their families, there is a valuable resource at the University of Kentucky providing information, support and hope.
UK's Sanders-Brown Center on Aging (SBCoA) was established in 1979 and is one of the original 10 National Institutes of Health-funded Alzheimer's Disease Research Centers. SBCoA is internationally acclaimed for its work in the fight against age-related diseases.
Faculty and researchers work together within the framework of the Center's mission to explore the aging process and its implications for society. Research spans bench to bedside, from defining disease mechanisms in the brain and exploring cellular changes that lead to AD, to studies exploring healthy aging and ways to lower risk of dementia, to clinical trials testing potential new therapies that slow or stop the progression of age-related diseases of the brain.
Watch the Big Blue Family video above to discover how Sanders-Brown has impacted Carolyn and Ron Borkowski and why philanthropy is so integral to ensuring UK researchers will contribute to finding a cure for Alzheimer’s disease while also helping other Kentucky families.
This video feature is part of a regular series produced by UKNow focusing on families who help make up the University of Kentucky community. There are many couples, brothers and sisters, mothers and sons and fathers and daughters who serve at UK in various fields or who are impacted by UK’s reach through the Commonwealth. The idea is to show how UK is part of so many families’ lives and how so many families are focused on helping the university succeed each and everyday.
Since the "Big Blue Family" series is now a monthly feature on UKNow, we invite you to submit future ideas. If you know of a family who you think should be featured, please email us. Who knows? We might just choose your suggestion for our next feature!
For more information on the Sanders-Brown Center on Aging, visit: http://www.uky.edu/coa/contact-information.
VIDEO CONTACTS: Amy Jones-Timoney, 859-257-2940, firstname.lastname@example.org or Kody Kiser, 859-257-5282, email@example.com
LEXINGTON, KY. (June 15, 2015) -- In Kentucky, a trifecta of risk factors contributes to high prevalence of lung cancer.
While high smoking rates and weak or non-existent smoke-free laws in Kentucky are undeniably linked to high rates of lung cancer, the soil underground also poses considerable dangers. Exposure to radon -- an odorless, tasteless gas that escapes from our limestone-enriched landscape, also increases a lung cancer risk. Finally, our laws don't adequately protect Kentuckians through mandated testing and monitoring of radon levels or smoke-free protections.
We need to be vigilant about monitoring both exposure to radon and second- and third hand smoke particles in the home. The risk of lung cancer increases 10-fold when a person is exposed to both high levels of radon and tobacco smoke. In fact, most cases of radon-induced lung cancer occur in those also exposed to tobacco smoke. Here are a few ways to reduce your risks:
Minimize your exposure to second- and third hand smoke. Radon gas and tobacco smoke particles stick to each other, and when both are inhaled, the damage to DNA in the body is elevated. Don't permit smoking in your home and car, where recirculating particles give off third hand smoke long after the visible smoke is gone. Do not permit smoking at least 20 feet from all entryways, vents and windows. When smoking outside, smokers need to cover their clothes with a jacket to avoid bringing third hand smoke into the home. Quitting smoking is the most important thing you can do to protect your health and your family.
Don't assume your home is radon-free. Testing your home for radon is easy and low-cost. Some health departments provide free test kits or you can buy one at most home improvement stores. If you're buying a home, test for radon during a home inspection. If you're a renter, ask your landlord about radon testing.
Test your home for radon every two years. All homes and buildings need to be monitored for radon levels every two years. If your home tests at an EPA rating of 4.0 or above, it's imperative to invest in a radon mitigation system. It doesn't matter if your home is old or new, or if your neighbors have low radon levels.
Get a professional to install a system to solve the problem. Cracking windows or ventilating a basement won't reduce levels of radon. If your radon levels are high, call a certified radon mitigation company to test your home.
If someone in your home smokes cigarettes, cigars, or pipes, you may be eligible to participate in a research study underway at the University of Kentucky examining combined effects of radon and smoke. For more information about the study, send an email to UKFRESH@LSV.UKY.EDU or call 859-323-4587.
Ellen Hahn, Ph.D., is a professor in the University of Kentucky College of Nursing and College of Public Health, and she directs the Clean Indoor Air Partnership and Kentucky Center for Smoke-Free Policy.
This appeared in the June 14, 2015 edition of the Lexington Herald-Leader
Join us on social media for health tips and news, as well as the latest on UK HealthCare events. You can also help us give the very best care by sharing your feedback.